Journal List > Ewha Med J > v.16(4) > 1083101

TOOLS
Lee: Phase II Study of Ifosfamide, Etoposide and Cisplatin(IEP) Chemotherapy for Advanced Non-Small Cell Lung Cancer
Original Article

The Ewha Medical Journal 1993; 16(4): 337-340.

Published online: 24 July 2015

DOI: https://doi.org/10.12771/emj.1993.16.4.337

Phase II Study of Ifosfamide, Etoposide and Cisplatin(IEP) Chemotherapy for Advanced Non-Small Cell Lung Cancer

Soon Nam Lee

Department of Internal Medicine, College of Medicine, Ewha Womans University, Korea.

Copyright © 1993. Ewha Womans University School of Medicine

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

To evaluste the efficacy and toxicity of IEP chemotherapy in locally advanced and metastatic non-small cell lung cancer, nineteen previously untreated patients with non-small cell lung cancer were studied.
Patients received ifosfamide 1000mg/m2 with mesna, 20% of ifosfamide dose at 0,4, 8 hours after ifosfamide, etoposide 100mg/m2, and cisplatin 20mg/m2 with full hydration and mannitol diuresis intravenously on days 1-3 every 4 weeks.
Eighteen male and one female, two stage IIIA, 10 stage IIIB and 7 stage IV patients have been treated.
The response rate of IEP was 26% with no complete remission, 53% of stable disease, and 23% of progressive diasease.
The overall median survival was not reaced yet and 20 month survival rate was 51.4%, The duration of remission was at the range of 4+ to 40 weeks.
The toxicities were alopecia(100%), nausea and vomiting(47%), leukopenia(14%), infection(6%), renal dysfunction(6%) and oral mucositis(5%).
This phase II study of IEP in advanced non-small cell lung cancer is not superior to another combination regimens in terms of response but toxicity was tolerable. Other new chemotherapeutic drugs and newer trials should be developed further.

TOOLS
Similar articles